Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)
NCT ID: NCT01307371
Last Updated: 2011-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
110 participants
OBSERVATIONAL
2007-03-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long Term Follow-up of Autologous Bone Marrow Mononuclear Cells Therapy in STEMI
NCT00626145
Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction
NCT04421274
Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia
NCT01937416
Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus
NCT01677013
Cell Therapy in Patients With Chronic Ischemic Heart Disease Undergoing Cardiac Surgery
NCT01267331
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetes
Patients with diabetes.
No interventions assigned to this group
non-diabetes
Patients without diabetes.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* STEMI according to the WHO definition
* PCI \<12 hours from the onset of symptoms
* LAD disease with an open infarct related artery
Exclusion Criteria
* cardiomyopathy
* atrial fibrillation or flutter
* previous heart surgery
* severe valvular heart disease
* disease of the hematopoietic system
* NYHA functional class IV heart failure at baseline
* severe renal, lung and liver disease
* cancer
* intra-cardiac thrombus
* bone marrow disease
25 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xijing Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xijing Hospital, Fourth Military Medical University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Feng Cao, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Air Force Military Medical University, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xijing Hospital
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DIABETES-STEMI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.